Contribution: Industrial Research Assistance Program – Contributions to Firms
Genvira Biosciences Inc.
$547,944.00
UK - Biomanufacturing - 10143729 - Heterologous Prime-boost Vaccination Induces Anti-tumor Immunity Against Melanoma.
EF 2025-26 · 2025-04-01
Résumé
“As part of the international consortium project “Cancer Immunotherapy: Heterologous prime-boost vaccination induces anti-tumor immunity against melanoma”, this project will …*
The firm will develop a novel immunotherapy to improve treatment options and prevent mortality and morbidity from advanced melanoma.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Ottawa|Ottawa, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
705625911
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2027-03-30
Agreement Number
1029005
Agreement Start Date
2025-04-01
Agreement Title
UK - Biomanufacturing - 10143729 - Heterologous Prime-boost Vaccination Induces Anti-tumor Immunity Against Melanoma.
Agreement Title (French)
Royaume-Uni - Biofabrication - 10143729 - La vaccination hétérologue par primovaccination-rappel induit une immunité antitumorale contre le mélanome.
Agreement Type
Contribution
Agreement Value
$547,944.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
“As part of the international consortium project “Cancer Immunotherapy: Heterologous prime-boost vaccination induces anti-tumor immunity against melanoma”, this project will …*
The firm will develop a novel immunotherapy to improve treatment options and prevent mortality and morbidity from advanced melanoma.
Description (French)
« Dans le cadre du projet de consortium international « Cancer Immunotherapy: Heterologous prime-boost vaccination induces anti-tumour immunity against melanoma », ce projet permettra de […]* L’entreprise développera une nouvelle immunothérapie pour améliorer les options de traitement et prévenir la mortalité et la morbidité liées au mélanome avancé.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ottawa South
Federal Riding (French)
Ottawa-Sud
Federal Riding Number
35077
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
705625911
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
Genvira Biosciences Inc.
Recipient Postal Code
K1V 1C1
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q4-1029005
